<DOC>
	<DOCNO>NCT03057977</DOCNO>
	<brief_summary>The aim study investigate safety efficacy empagliflozin versus placebo top guideline-directed medical therapy patient heart failure reduce ejection fraction .</brief_summary>
	<brief_title>EMPagliflozin outcomE tRial Patients With chrOnic heaRt Failure With Reduced Ejection Fraction ( EMPEROR-Reduced )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Male female patient age &gt; = 18 year screen . For Japan : Age &gt; = 20 year screen Patients chronic HF ( Chronic Heart Failure ) NYHA ( New York Heart Association Classification ) class IIIV reduce EF ( Ejection Fraction ) ( LVEF ( Left Ventricular Ejection Fraction ) &lt; =40 % ) elevate NTproBNP ( Nterminal prohormone brain natriuretic peptide ) If EF &gt; = 36 % &lt; = 40 % : NTproBNP &gt; = 2500 pg/ml If EF &gt; = 31 % &lt; = 35 % : NTproBNP &gt; = 1000 pg/ml If EF &lt; = 30 % NTproBNP &gt; = 600 pg/ml Appropriate dose medical therapy HF consistent prevail local international CV ( Cardiovascular ) guideline , stable least 1 week prior Visit 1 Appropriate use medical device cardioverter defibrillator ( ICD ) cardiac resynchronization therapy ( CRT ) consistent prevail local international CV guideline , unless implant within 3 month prior Visit 1 Signed date write ICF ( Informed Consent Form ) Further inclusion criterion apply Exclusion criterion : Myocardial infarction , coronary artery bypass graft surgery , major cardiovascular surgery , stroke TIA ( Transient Ischaemic Attack ) past 90 day prior Visit 1 Heart transplant recipient , list heart transplant Acute decompensated HF Systolic blood pressure ( SBP ) &gt; = 180 mmHg Visit 2 . Symptomatic hypotension and/or SBP &lt; 100 mmHg Indication liver disease Impaired renal function , define eGFR ( Estimated Glomerular Filtration Rate ) &lt; 20 mL/min/1.73 m2 ( CKDEPI ( Chronic Kidney Disease Epidemiology Collaboration Equation ) ) require dialysis History ketoacidosis Treatment SGLT ( Sodiumglucose cotransporter ) 2 inhibitor combine SGLT1 2 inhibitor Currently enrol another investigational device drug study Known allergy hypersensitivity empagliflozin SGLT2 inhibitor Women pregnant , nursing , plan become pregnant trial Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>